SCOTTSDALE, Ariz., April 27, 2010 (GLOBE NEWSWIRE) -- Medicis (NYSE:MRX) today announced it has extended the "Dysport Challenge: Love It or Leave It" for Dysport (abobotulinumtoxinA) 300 Units for Injection through May 31, 2010, due to its popularity. Approved by the U.S. Food and Drug Administration (FDA) in April 2009, Dysport is a prescription injection used to temporarily improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults less than 65 years of age.
